Pharma BD Deal Intelligence
Ono's $2.4 billion acquisition of Deciphera has already paid off: QINLOCK anchored a new oncology footprint, and the vimseltinib bet delivered—ROMVIMZA won FDA approval for tenosynovial giant cell tumor in February 2025, then EU approval in September 2025 as the first authorized TGCT therapy there.
Deciphera Pharmaceuticals to be acquired by ONO Pharmaceutical for $2.4 billion at $25.60 per share a 74.7 percent premium adding QINLOCK and vimseltinib…
Ono acquired Deciphera for $2.4B for Qinlock (ripretinib) for GI stromal tumors.
Deciphera receives European Commission approval of ROMVIMZA (vimseltinib) for the treatment of tenosynovial giant cell tumor (TGCT), September 17, 2025 -- the…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Ono Pharmaceutical acquired Deciphera Pharmaceuticals for approximately $2.4 billion ($25.60/share cash, a 74.7% premium), announced April 29, 2024 and closed June 11, 2024 via tender offer, making Deciphera a wholly owned Ono subsidiary. The deal gave Ono its lead commercial asset QINLOCK (ripretinib), a switch-control KIT/PDGFRA inhibitor approved for fourth-line GIST (full-year 2023 net product revenue $159.1M), plus the late-stage candidate vimseltinib, an oral CSF1R inhibitor for tenosynovial giant cell tumor (TGCT), establishing Ono a U.S. and European commercial oncology footprint. The vimseltinib thesis has since been realized: the FDA granted full approval of ROMVIMZA (vimseltinib) for symptomatic TGCT on February 14, 2025 -- the second approved drug from Deciphera's switch-control kinase platform -- followed by European Commission approval on September 17, 2025, where it is the first and only authorized TGCT therapy. The acquisition's growing-portfolio rationale is intact and de-risked, with two approved commercial products across the U.S. and EU.
Qinlock (ripretinib) is the 4L+ standard in advanced GIST but franchise expansion is constrained by a crowded KIT/PDGFRA TKI landscape. Broad-spectrum KIT/PDGFRA switch-control TKIs (class where ripretinib sits): Qinlock FDA-approved 2020 4L+ GIST per INVICTUS (Lancet Oncology 2020), with Deciphera 2023 product sales of roughly $170M; no direct second-in-class switch-control approved. Selective KIT/PDGFRA inhibitors by line: Gleevec (imatinib, Novartis/generic) 1L standard since 2002 (now generic, widely available); Sutent (sunitinib, Pfizer/generic) approved 2L after imatinib failure; Stivarga (regorafenib, Bayer) approved 3L (GRID Phase 3); Iclusig (ponatinib, Takeda) used off-label. PDGFRA D842V-selective TKIs: Ayvakit (avapritinib, Blueprint Medicines) FDA-approved 2020 for PDGFRA exon 18 (including D842V)-mutant unresectable GIST per NAVIGATOR, a distinct small biomarker-defined niche roughly 5-6% of GIST; INVICTUS showed no survival benefit in unselected populations preventing earlier-line expansion. Emerging competition: bezuclastinib (Cogent Biosciences) in Phase 3 PEAK trial versus sunitinib in 2L GIST threatens Qinlock's refractory positioning and would compress the 2L/3L addressable population; olverembatinib (Ascentage) also in development. Commercial threat is bezuclastinib readout in 2L and Ono's failed INTRIGUE Phase 3 (ripretinib vs sunitinib 2L) which blocked earlier-line label expansion.
DCC-3009 is Ono/Deciphera's next-generation KIT inhibitor in early clinical development designed to address resistance mutations not covered by ripretinib; it enters a tightly defined advanced-GIST MOA map. Next-generation mutant-selective KIT inhibitors (direct class): DCC-3009 is in Phase 1; bezuclastinib (Cogent Biosciences) is the most advanced competitor in Phase 3 PEAK trial (bezuclastinib + sunitinib versus sunitinib in 2L post-imatinib GIST) and Phase 2 APEX in 4L+ GIST, representing the primary commercial threat; THE-630 (Theseus/Concentra) was discontinued. Broad-spectrum KIT/PDGFRA switch-control inhibitors: Qinlock (ripretinib, Ono/Deciphera) approved 4L+ but failed INTRIGUE 2L (versus sunitinib); Ayvakit (avapritinib, Blueprint) restricted to PDGFRA D842V. First and second-generation KIT/PDGFRA TKIs: Gleevec (imatinib, Novartis/generic) 1L standard; Sutent (sunitinib, Pfizer/generic) 2L; Stivarga (regorafenib, Bayer) 3L. Other investigational: olverembatinib (Ascentage/HUYABIO) in Phase 2/3 in imatinib-resistant GIST; IDRX-42 (IDRx, acquired by GSK 2025) in Phase 1 targeting primary and secondary KIT mutations. Commercial threat for DCC-3009: bezuclastinib's 2-3 year head start into Phase 3 and GSK's IDRx acquisition signal big-pharma competition for the next-gen KIT space; Ono must accelerate DCC-3009 into combination or differentiated resistance-mutation strategies to preserve Qinlock franchise continuity.
Romvimza (vimseltinib) is a selective oral CSF1R switch-control kinase inhibitor approved by the FDA in February 2025 for symptomatic TGCT not amenable to surgery, based on the Phase 3 MOTION trial. The competitive landscape groups into three MOA classes: oral CSF1R kinase inhibitors, anti-CSF1R monoclonal antibodies, and surgical standard of care. In the oral CSF1R TKI class, Daiichi Sankyo's Turalio (pexidartinib) was the first approved TGCT agent (FDA 2019) but carries a black-box hepatotoxicity warning and REMS program that have constrained uptake, with commercial sales below $100M per year based on Daiichi disclosures. Vimseltinib's cleaner hepatic profile positions it as the category challenger. On the anti-CSF1R antibody axis, emactuzumab (Celleron Therapeutics, Phase 3 TANGENT) is in late-stage development, and AMB-05X (AmMax Bio, intraarticular CSF1R antibody) is in Phase 2 for a locally delivered option. Older kinase inhibitors with anti-CSF1R activity including imatinib (Gleevec, generic, off-label) and nilotinib (Tasigna, Novartis) retain residual off-label use but lack TGCT labels and deliver inferior response rates. Surgical resection remains first-line for localized disease but recurrence rates of 40-50% drive the systemic market. Commercial takeaway: Romvimza enters a two-player oral market where the incumbent is hobbled by toxicity, offering a credible share-take thesis.
Ono Pharmaceutical completed $2.4B acquisition of Deciphera, gaining Qinlock (ripretinib) for GIST and vimseltinib for TGCT.
FDA granted full approval of ROMVIMZA (vimseltinib), an oral CSF1R inhibitor, for adults with symptomatic TGCT where surgery would cause worsening functional limitation or severe morbidity. Second approved drug from Deciphera's switch-control kinase platform; gives Ono a second commercial oncology product post-acquisition.
European Commission approved ROMVIMZA (vimseltinib) for symptomatic TGCT on September 17, 2025 -- the first and only authorized TGCT therapy in the EU, extending Ono/Deciphera's commercial reach beyond the U.S.
Qinlock provides established GIST revenue, vimseltinib could add second indication. $2.4B gives Ono meaningful US oncology presence. Early trajectory positive.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Ono Pharmaceutical Co., Ltd. / Deciphera Pharmaceuticals (this deal) | 2024 | $2.4B | 69 |
| Ono Pharmaceutical Co., Ltd. / Monash University | 2024 | — | — |
| Ono Pharmaceutical Co., Ltd. / Congruence Therapeutics | 2024 | — | — |
| Ono Pharmaceutical Co., Ltd. / LigaChem Biosciences, Inc. | 2024 | $700M | — |
| Ono Pharmaceutical Co., Ltd. / PRISM BioLab | 2024 | — | — |
| Ono Pharmaceutical Co., Ltd. / Ionis Pharmaceuticals, Inc. | 2025 | $940M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
← Browse all deals · How we score deals
More: 2024 deals · Ono Pharmaceutical Co., Ltd. deals · Oncology deals